Sana Biotechnology, Inc.
As of Oct 22, 2026, Sana Biotechnology is in Stage 4, the downtrend phase, now in week 5 (since Sep 24, 2026). It closed at $2.37, 57.6% below its 52-week high and below its 200-day average, which is falling.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SANA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SANA among Biotechnology393rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …393 | SANA | Stage 4 · wk 5 | 19 | −23.1% |
Sana Biotechnology: quick answers
What stage is Sana Biotechnology in?
As of Oct 22, 2026, Sana Biotechnology (SANA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 24, 2026 and is in week 5. What the four stages mean
Is Sana Biotechnology in an uptrend?
No. Sana Biotechnology is in a Stage 4 downtrend. It trades 31.4% below its 200-day average, which is falling.
How far is Sana Biotechnology from its 52-week high?
Sana Biotechnology closed at $2.37 on Oct 22, 2026, 57.6% below its 52-week high of $5.59. Its 52-week low is $2.27.
How has Sana Biotechnology performed over the past year?
As of Oct 22, 2026, Sana Biotechnology is down 58.5% over the past year and down 43.4% so far in 2026.
Which sector and industry is Sana Biotechnology in?
Sana Biotechnology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.